- Reuters
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.
- Yahoo財經
美股日誌｜納指首破萬七點 英偉達爆上7%
美股在假期後先升後回，受惠英偉達上達1,100美元帶動，納斯達克指數曾歷史性突破17,000點以上，午市一度近抹去所有升幅，惟最終能守穩在心理關口收市；道瓊斯指數曾跌近300點，標普500指數則近平收。債市向下，美國國債拍賣需求弱，10年期國債息率升7點子以上。中東局勢升溫，紐約期油升2.7%。
- Benzinga
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
